<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Childhood <z:hpo ids='HP_0001909'>leukemia</z:hpo>, which accounts for &gt;30% of newly diagnosed childhood <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, is one of the leading causes of <z:hpo ids='HP_0011420'>death</z:hpo> for children with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Genome-wide studies using microarray chips to identify copy number changes in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> are becoming more common </plain></SENT>
<SENT sid="2" pm="."><plain>In this pilot study, 45 pediatric <z:hpo ids='HP_0001909'>leukemia</z:hpo> samples were analyzed for gene copy aberrations using novel molecular inversion probe (MIP) technology </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0002488'>Acute leukemia</z:hpo> subtypes included precursor B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) (n=23), precursor T-cell ALL (n=6), and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (n=14) </plain></SENT>
<SENT sid="4" pm="."><plain>The MIP analysis identified 69 regions of recurring copy number changes, of which 41 have not been identified with other DNA microarray platforms </plain></SENT>
<SENT sid="5" pm="."><plain>Copy number gains and losses were validated in 98% of clinical karyotypes and 100% of fluorescence in situ hybridization studies available </plain></SENT>
<SENT sid="6" pm="."><plain>We report unique patterns of copy number loss in samples with 9p21.3 (CDKN2A) deletion in the precursor B-cell ALL patients, compared with the precursor T-cell ALL patients </plain></SENT>
<SENT sid="7" pm="."><plain>MIPs represent an attractive technology for identifying novel copy number aberrations, validating previously reported copy number changes, and translating molecular findings into clinically relevant targets for further investigation </plain></SENT>
</text></document>